Reshma Kewalramani's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 15,580 Common Stock done at an average price of $495.4 . Disclosure was reported to the exchange on Feb. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 495.38 per share. | 27 Feb 2026 | 15,580 | 105,998 (0%) | 0% | 495.4 | 7,718,020 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 496.16 per share. | 27 Feb 2026 | 5,995 | 100,003 (0%) | 0% | 496.2 | 2,974,479 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 494.33 per share. | 27 Feb 2026 | 3,498 | 121,578 (0%) | 0% | 494.3 | 1,729,166 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 488.27 per share. | 27 Feb 2026 | 3,278 | 131,730 (0%) | 0% | 488.3 | 1,600,549 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 490.54 per share. | 27 Feb 2026 | 2,725 | 128,545 (0%) | 0% | 490.5 | 1,336,722 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 493.29 per share. | 27 Feb 2026 | 2,520 | 125,076 (0%) | 0% | 493.3 | 1,243,091 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 487.13 per share. | 27 Feb 2026 | 2,510 | 135,008 (0%) | 0% | 487.1 | 1,222,696 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 496.95 per share. | 27 Feb 2026 | 1,725 | 98,278 (0%) | 0% | 497.0 | 857,239 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 491.30 per share. | 27 Feb 2026 | 949 | 127,596 (0%) | 0% | 491.3 | 466,244 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 489.32 per share. | 27 Feb 2026 | 460 | 131,270 (0%) | 0% | 489.3 | 225,087 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 479.75 per share. | 27 Feb 2026 | 400 | 137,878 (0%) | 0% | 479.8 | 191,900 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 482.84 per share. | 27 Feb 2026 | 240 | 137,518 (0%) | 0% | 482.8 | 115,882 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 481.50 per share. | 27 Feb 2026 | 120 | 137,758 (0%) | 0% | 481.5 | 57,780 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 485.11 per share. | 24 Feb 2026 | 4,981 | 138,278 (0%) | 0% | 485.1 | 2,416,333 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 16,326 | 149,813 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.75 per share. | 17 Feb 2026 | 6,554 | 143,259 (0%) | 0% | 483.8 | 3,170,498 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 487.76 per share. | 13 Feb 2026 | 13,041 | 133,487 (0%) | 0% | 487.8 | 6,360,878 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 468.41 per share. | 10 Feb 2026 | 8,297 | 146,528 (0%) | 0% | 468.4 | 3,886,398 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2026 | 26,972 | 142,940 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2026 | 11,885 | 154,825 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 389.95 per share. | 06 Aug 2025 | 5,710 | 115,968 (0%) | 0% | 390.0 | 2,226,615 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 389.08 per share. | 06 Aug 2025 | 4,290 | 110,258 (0%) | 0% | 389.1 | 1,669,153 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 14,079 | 105,915 (0%) | 0% | 479.6 | 6,752,429 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 9,386 | 119,994 (0%) | 0% | 483.3 | 4,536,066 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 6,553 | 129,380 (0%) | 0% | 463.5 | 3,037,053 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 19,015 | 135,933 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 8,300 | 116,918 (0%) | 0% | 468.0 | 3,884,234 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 29,118 | 104,890 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 20,328 | 125,218 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 515.00 per share. | 08 Nov 2024 | 15,198 | 75,772 (0%) | 0% | 515 | 7,826,970 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 505.00 per share. | 30 Jul 2024 | 15,202 | 90,970 (0%) | 0% | 505 | 7,677,010 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 497.00 per share. | 22 Jul 2024 | 15,202 | 106,172 (0%) | 0% | 497 | 7,555,394 | Common Stock |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 0 | - | - | Restricted Stock Units | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 186,002 | - | - | Class A Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 24 May 2024 | 1,565 | 122,939 (0%) | 0% | 187.5 | 293,484 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2024 | 1,565 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 457.00 per share. | 24 May 2024 | 1,565 | 121,374 (0%) | 0% | 457 | 715,205 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 447.00 per share. | 20 May 2024 | 15,202 | 121,374 (0%) | 0% | 447 | 6,795,294 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 9,386 | 136,507 (0%) | 0% | 431.8 | 4,052,781 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 9,359 | 152,912 (0%) | 0% | 424.0 | 3,968,310 | Common Stock |
| Vertex Pharma | Kewalramani Reshma | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 7,019 | 145,893 (0%) | 0% | 420.6 | 2,952,051 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 8,255 | 162,271 (0%) | 0% | 422.7 | 3,489,719 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 26,972 | 150,199 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kewalramani Reshma | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 20,327 | 170,526 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kewalramani Reshma | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 14,516 | 123,227 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kewalramani Reshma | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 407.00 per share. | 15 Dec 2023 | 17,135 | 108,711 (0%) | 0% | 407 | 6,973,945 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 14,077 | 1,565 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Kewalramani Reshma | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 15 Dec 2023 | 14,077 | 125,846 (0%) | 0% | 187.5 | 2,639,860 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 3,058 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Kewalramani Reshma | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 15 Dec 2023 | 3,058 | 111,769 (0%) | 0% | 155.6 | 475,733 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 397.00 per share. | 13 Dec 2023 | 5,098 | 108,711 (0%) | 0% | 397 | 2,023,906 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 355.00 per share. | 17 Jul 2023 | 7,828 | 118,906 (0%) | 0% | 355 | 2,778,940 | Common Stock |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 139,860 | 139,860 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 105,263 | 105,263 | - | - | Restricted Stock Units | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 339.43 per share. | 27 Apr 2023 | 1,668 | 126,690 (0%) | 0% | 339.4 | 566,169 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 338.69 per share. | 27 Apr 2023 | 1,611 | 128,358 (0%) | 0% | 338.7 | 545,630 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 340.18 per share. | 27 Apr 2023 | 38 | 126,652 (0%) | 0% | 340.2 | 12,927 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 9,386 | 129,969 (0%) | 0% | 289.1 | 2,713,680 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 9,359 | 139,355 (0%) | 0% | 292.8 | 2,740,783 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 148,714 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,372 | 154,704 (0%) | 0% | 294.3 | 992,481 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 29,118 | 131,104 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 26,972 | 158,076 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 101,986 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 315.05 per share. | 25 Jan 2023 | 10,000 | 89,598 (0%) | 0% | 315.1 | 3,150,500 | Common Stock |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 9,818 | 80,739 | - | - | Class A Common Stock | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 9,818 | 0 | - | - | Restricted Stock Units | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 305.06 per share. | 15 Aug 2022 | 11,689 | 99,598 (0%) | 0% | 305.1 | 3,565,846 | Common Stock |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 108,516 | 108,516 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 70,921 | 70,921 | - | 0 | Class A Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 7,246 | 122,842 (0%) | 0% | 227.9 | 1,651,074 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 8,584 | 130,088 (0%) | 0% | 232.5 | 1,995,866 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.74 per share. | 10 Feb 2022 | 3,031 | 138,672 (0%) | 0% | 237.7 | 720,590 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 29,117 | 141,703 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 29,032 | 112,586 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 9,800 | 83,554 (0%) | 0% | 0 | Common Stock | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 9,818 | 9,818 | - | - | Restricted Stock Units | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2021 | 51,782 | 51,782 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings Inc (Class A) | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2021 | 17,649 | 17,649 | - | - | Stock Option | |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 195.14 per share. | 19 Aug 2021 | 5,757 | 69,511 (0%) | 0% | 195.1 | 1,123,421 | Common Stock |
| Vertex Pharma | Reshma Kewalramani | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 196.34 per share. | 19 Aug 2021 | 4,243 | 73,754 (0%) | 0% | 196.3 | 833,071 | Common Stock |